Personalized Gait Retraining to Support Knee Health in Older Adults (BiofeedbackRCT)

November 15, 2026 updated by: Lauri Stenroth, University of Eastern Finland

A Real-time Biofeedback Intervention for Improving Tibiofemoral Cartilage Quality in Older Adults

Participants are randomized into two groups: gait retraining and habitual walking. In the gait retraining group, an intervention consisting of 10 training sessions on a treadmill aims to reduce medial tibiofemoral joint loading during walking. Real-time visual biofeedback on a knee joint loading metric is provided during some of the training sessions to facilitate learning. The habitual walking group participates in an equal number of training sessions where they perform their habitual walking and do not try to change their walking technique. Changes in knee joint cartilage properties are assessed at 5 months.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

In this randomized controlled intervention study, participants are randomized into two groups: gait retraining and habitual walking. At baseline and five months later, participants' gait mechanics and knee joint cartilage structure and quality are assessed, and blood and urine samples and questionnaire data are collected. In addition, knee joint radiographic status is assessed at baseline. Physical activity is monitored using a thigh-worn accelerometer throughout the study.

The intervention consisting of 10 training sessions on a treadmill aims to reduce medial tibiofemoral joint loading during walking. During the first session, participants try different kinematics-based gait modifications to personalize the intervention. The modifications that reduce estimated medial tibiofemoral knee joint loading the most are selected and utilized during the following sessions. The gait retraining aims at establishing a gait pattern for each individual that reduces medial tibiofemoral joint loading while also being such that the person can utilize it in their daily living. To support learning and fine-tuning the gait pattern, real-time feedback on knee joint moments is provided during part of the training sessions. The habitual walking group participates in an equal number of training sessions where they perform their habitual walking and do not try to change their walking technique. Eight of the training sessions are conducted within four weeks, while the two remaining sessions (so-called boosters) are conducted during the following four months with the aim of supporting maintenance of the learned gait pattern.

Pre-planned additional follow-ups are planned for 12 and 24 months from baseline. Knee MRI would be conducted at these follow-up points, with implementation depending on funding.

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 74 years (Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age above 65 or below 75 years (in full years)
  • Access to a smartphone or tablet with an Android or iOS operating system

Exclusion Criteria:

  • Unable to walk for 30 minutes without stopping and without an assistive device
  • Body mass index <18 or >30 kg/m2
  • Pain during walking
  • Diagnosed with knee osteoarthritis
  • Moderate (KL Grade 3) or severe (KL Grade 4) radiographical tibiofemoral osteoarthritis based on Kellgren-Lawrence (KL) Classification of Osteoarthritis
  • Diagnosed with neurological disease
  • Surgery of the knee joint
  • Surgery or injury to the lower limbs causing pain or affecting mobility
  • Current musculoskeletal injury causing pain or affecting mobility
  • Contraindication for magnetic resonance imaging
  • Contraindication for walking-based exercise training (e.g., cardiovascular symptoms that increase with exercise or recommendation from a medical professional to avoid moderate exercise)
  • Any other condition that, in the opinion of the investigator, makes a potential participant unfit for participation or conditions that put a potential participant at risk by participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Gait retraining

The arm receives personalized gait retraining via treadmill walking and real-time feedback.

Personalized gait retraining using small kinematic alterations guided by real-time feedback of knee joint loading. The training is perfomed on a treadmill.

Other: Habitual walking

The arm receives equal amount of treadmill walking without feedback or instruction to alter the gait.

Participants receive equal amount of treadmill walking as the ones receiving gait retraining intervention. This intervention serves as the comparator for the gait retraining intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Medial tibiofemoral T1ρ relaxation time
Time Frame: Baseline and 5 months

T1ρ relaxation time map of tibiofemoral cartilage from the medial compartment of the knee joint assessed using 3T MRI

Baseline and 5 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Medial tibiofemoral T2 relaxation time
Time Frame: Baseline and 5 months

T2 relaxation time map of tibiofemoral cartilage from the medial compartment of the knee joint assessed using 3T MRI

Baseline and 5 months
Lateral tibiofemoral T1ρ relaxation time
Time Frame: Baseline and 5 months

T1ρ relaxation time map of tibiofemoral cartilage from the lateral compartment of the knee joint assessed using 3T MRI

Baseline and 5 months
Lateral tibiofemoral T2 relaxation time
Time Frame: Baseline and 5 months

T2 relaxation time map of tibiofemoral cartilage from the lateral compartment of the knee joint assessed using 3T MRI

Baseline and 5 months
Tibiofemoral loading during walking
Time Frame: Baseline and 5 months

Tibiofemoral loading during walking assessed using musculoskeletal simulation

Baseline and 5 months
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: Baseline and 5 months

The score range is from 0 to 100. 0 represents extreme problems / worst possible knee symptoms. 100 represents no problems / perfect knee health.

Baseline and 5 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
High-sensitivity C-reactive protein (hs-CRP)
Time Frame: Baseline and 5 months

hs-CRP (mg/L) is measured from blood samples using a particle-enhanced immunoturbidimetric assay as a marker of systemic inflammation.

Baseline and 5 months
Glycated hemoglobin (HbA1c)
Time Frame: Baseline and 5 months

HbA1c (mmol/mol) is measured from blood samples using turbidimetric inhibition immunoassay as a marker of long-term blood glucose control.

Baseline and 5 months
Knee cartilage recovery rate after loading assessed from magnetic resonance images
Time Frame: Baseline and 5 months

The knee joint is loaded with 20 minutes of standing and followed by repeated magnetic resonance imaging. Cartilage is segmented from the images, and the temporal recovery of the cartilage thickness in the medial tibiofemoral joint is quantified. The unit is mm/min.

Baseline and 5 months
Proteomic analysis of serum samples
Time Frame: Baseline and 5 months

Liquid chromatography-mass spectrometry is used to run non-targeted peptide analysis of serum proteins. This is a pre-planned exploratory analysis that identifies hundreds of proteins and their concentration in the sample.

Baseline and 5 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lauri Stenroth, PhD, University of Eastern Finland

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2026

Primary Completion (Estimated)

February 28, 2028

Study Completion (Estimated)

March 31, 2028

Study Registration Dates

First Submitted

November 4, 2026

First Submitted That Met QC Criteria

November 15, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 125/2025
  • 363854 (Other Grant/Funding Number: Research Council of Finland)
  • FIMEA/2025/007528-5 (Other Identifier: Finnish Medicines Agency)
  • 125/2025 (Other Identifier: The Regional Medical Research Ethics Committee of Eastern Finland Collaborative Area)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD used in the publications is planned to be shared.

IPD Sharing Time Frame

At the time of publication with no end date.

IPD Sharing Access Criteria

Open access to the IPD and supporting information to be used in scientific research. If possible, the data is made available at the time of publishing the results with link to the data repository at the publication.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe